论文部分内容阅读
目的:探讨β-受体阻滞剂对高血压伴阵发性房颤患者P波最大时限(Pmax)及P波离散度(Pd)的影响。方法:高血压伴阵发性房颤患者60例被随机分为美托洛尔治疗组(A组,30例)和对照组(B组,30例),两组高血压降压治疗基本相同,都使用钙阻抗剂或ACEI类药。A组加用美托洛尔25-50 mg/d。在治疗前、治疗后6个月分别测量Pmax和P波最短时间(Pmin),计算出Pd(Pd=Pmax-Pmin)。结果:治疗前两组Pmax和Pd比较无显著差异(P>0.05);治疗6个月A组的Pmax、Pd显著降低,与B组相同时间比较差异有非常显著性(P<0.01);A组治疗前与治疗后6个月比较Pmax、Pd相差有显著性(P<0.01);而B组间相差不显著(P>0.05)。A组房颤发作次数明显减少,与B组比较差异有非常显著性(P<0.01)。结论:β-受体阻滞剂治疗高血压伴阵发性房颤患者可明显降低Pmax、Pd,减少房颤发作次数。
Objective: To investigate the effects of β-blocker on P max and P wave dispersion in patients with hypertension and paroxysmal atrial fibrillation. Methods: Sixty patients with hypertension and paroxysmal atrial fibrillation were randomly divided into metoprolol treatment group (A group, 30 cases) and control group (B group, 30 cases). The two groups were basically the same , Are using calcium resistance agent or ACEI drugs. A group with metoprolol 25-50 mg / d. Before treatment and 6 months after treatment, the shortest Pmax and P wave were measured, and Pd (Pd = Pmax-Pmin) was calculated. Results: There was no significant difference in Pmax and Pd between the two groups before treatment (P> 0.05). The Pmax and Pd of group A decreased significantly at 6 months after treatment, and the difference was significant at the same time as group B (P <0.01); A The difference of Pmax and Pd between before treatment and 6 months after treatment was significant (P <0.01), while there was no significant difference between B groups (P> 0.05). The frequency of atrial fibrillation in group A decreased significantly compared with that in group B (P <0.01). Conclusion: β-blockers in patients with hypertension and paroxysmal atrial fibrillation can significantly reduce Pmax, Pd, reduce the number of episodes of atrial fibrillation.